The NGAL TestTM
A tool for risk assessment of kidney damage designed to help you get ahead of the creatinine clock
Pending FDA 510(k) clearance.
Talk with Us about NGAL
The NGAL Test™*
Until now, assessing risk of Acute Kidney Injury (AKI) in critically ill children has relied on changes in serum creatinine and urine output, physiologic endpoints that are delayed, non-specific, and impacted by extrarenal factors such as nutrition status and muscle mass.
The NGAL Test* is designed to help clinicians identify levels of urinary NGAL, a biomarker that rises rapidly in response to kidney injury, preceding changes in creatinine by as much as 2 to 3 days.i
By identifying patients at risk of AKI early, clinicians can take more appropriate action to manage fluid levels, avoid nephrotoxic agents, and potentially prevent permanent, kidney damage.i
*Pending FDA 510(k) clearance.
Take action for those at risk of AKI – NGAL responds to kidney injury 2 to 3 days before creatinine
Urine sample, runs on standard chemistry analyzers
Designed to identify who is at risk of developing moderate to severe AKI within 48 hours of PICU admission
Improved management of AKI can reduce LOS, minimize unnecessary interventions, and inform treatment choices
The NGAL Test is pending FDA 510(k) clearance.
Identification of AKI Risk
The NGAL biomarker has been shown to offer early clinical decision support to guide patient management.
Adapted from: Murray PT, Mehta RL, Shaw A, et al. Potential use of biomarkers in acute kidney injury report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 2014.85(3):513-521 and Stanski N, Menon S, Goldstein SL, Basu RJ. Integration of urinary neutrophil gelatinase-associated lipocalin with serum creatinine delineates acute kidney injury phenotypes in critically ill children. Journal Critical Care. 2019.53:1-7.
i Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265–280.